Single-blind and controlled comparative study of lamotrigine with zonisamide for refractory pediatric epilepsy

Journal of the Japan Epilepsy Society

Volumn 25, Issue 4, 2007, Pages 425-440

  Ohtahara, Shunsuke ^a   Iinuma, Kazuie ^b   Fujiwara, Tateki ^c   Yamatogi, Yasuko ^d  

^a OKAYAMA UNIVERSITY   (Japan)

^b Ishinomaki Red Cross Hospital

^c SHIZUOKA INSTITUTE OF EPILEPSY AND NEUROLOGICAL DISORDERS   (Japan)

^d OKAYAMA PREFECTURAL UNIVERSITY   (Japan)

Author keywords

Adjunctive therapy; Lamotrigine; Lennox Gastaut syndrome; Refractory childhood epilepsy; Single blind study

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; LAMOTRIGINE; ZONISAMIDE;

ADOLESCENT; ANOREXIA; ARTICLE; BENIGN CHILDHOOD EPILEPSY; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DECREASED APPETITE; DISEASE EXACERBATION; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; RASH; SEIZURE; SINGLE BLIND PROCEDURE; SOMNOLENCE; STEVENS JOHNSON SYNDROME; URTICARIA;

EID: 41549134653     PISSN: 09120890     EISSN: 13475509     Source Type: Journal    
DOI: 10.3805/jjes.25.425     Document Type: Article

References (16)

1. National Institute for Health and Clinical Excellence. The epilepsies - The diagnosis in adults and children in primary and secondary care: (Online) available from http://guidance.nice.org.uk/CG20〉 (accessed 2007-10-07).
2. Besag FM, Wallace SJ, Dulac O, Alving J, Spencer SC, Hosking G. Lamotrigine for the treatment of epilepsy in childhood. The Journal of Pediatrics 1995; 127: 991-997.
3. Motte J, Trevathan E, Arvidsson JF, Barrera MN, Mullens EL, Manasco P. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group. N Engl J Med 1997; 337: 1807-1812.
4. Schubert R. Attention deficit disorder and epilepsy. Pediatr Neurol 2005; 32: 1-10.
5. Messenheimer JA, Giorgi L, Risner ME. The tolerability of lamotrigine in children. Drug Saf 2000; 22: 303-312.
6. Hirsch LJ, Weintraub DB, Buchsbaum R, Spencer HT, Straka T, Hager M, et al. Predictors of lamotrigine-associated rash. Epilepsia 2006; 47: 318-322.
7. Messenheimer J, Mullens EL, Giorgi L, Young F. Safety review of adult clinical trial experience with lamotrigine. Drug Saf 1998; 18: 281-296.
8. Mockenhaupt M, Messenheimer J, Tennis P, Schlingmann J. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology 2005; 64: 1134-1138.
9. Cohen AF, Land DG, Breimer DD, Yuen WC, Winton C, Peck AW. Lamotrigine, a new anticonvulsant: Pharmacokinetics in normal humans. Clin Pharmacol Ther 1987; 42: 535-541.
10. Chen C, Casale EJ, Duncan B, Culverhouse EH, Gilman J. Pharmacokinetics of lamotrigine in children in the absence of opther antiepileptic drugs. Pharmacotherapu 1999; 19: 437-441.
11. Vauzelle-Kervroedan F, Rey E, Cieuta C, Pariente-Khayat A, Pons G, d'Athis P, et al. Influence if concurrent antiepileptic on the pharmacokinetics of lamotrigine as add-on therapy in epileptic children. Br J Clin Pharmacol 1996; 41: 325-330.
12. Pollard JR, Delanty N. Antiepileptic drug interactions. Continuum Lifelong Learning Neurol 2007; 13: 91-105.
13. Peck AW. Clinical Pharmacology of Lamotrigine. Epilepsia 1991; 132 (Suppl. 2): S 9-S 12.
14. Kilpatrick ES, Forrest G, Brodie MJ. Concentration-effect and concentration-toxicity relations with lamotrigine: A prospective study. Epilepsia 1996; 37: 534-538.
15. Japanese source
16. Matsuo F, Bergen D, Faught E, Messenheimer JA, Dren AT, Rudd GD, et al. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. Neurology 1993; 43: 2284-2291.